Clinical trial · Interventional
Taste, Smell and Chemotherapy (TASTY)
Taste and Smell Changes in Testicular Cancer Patients Treated With Cisplatin Based Chemotherapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Taste and smell abnormalities are common in cancer patients undergoing chemotherapy, with a prevalence ranging from 46% to 77% for taste changes, and 35% to 75% for smell changes. These chemosensory changes are distressing for patients and can lead to changes in appetite, food choice, and nutrient intake. These changes can result in malnutrition and weight loss. Possibly, also unhealthy eating patterns can be developed due to these taste and smell changes, given the high prevalence of obesity among survivors of certain cancer types. The primary objective is to investigate the nature, prevalence, and duration of taste and smell changes in patients with disseminated testicular cancer treated with cisplatin based chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Testicular Cancer | Malignant Testicular Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (7)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| audiogram | Procedure | — | UNRESOLVED |
| Dexa scan | Procedure | — | UNRESOLVED |
| Food Frequency Questionnaire | Behavioral | — | UNRESOLVED |
| Glucose tolerance assessment | Procedure | — | UNRESOLVED |
| measurement of heart rate variability and baroreflex sensitivity | Procedure | — | UNRESOLVED |
| oral nutrition supplements | Dietary Supplement | — | UNRESOLVED |
| Two day food records | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Patients
- description
- Patients with disseminated testicular cancer
- interventionNames
- Procedure: Dexa scan
- Procedure: audiogram
- Procedure: measurement of heart rate variability and baroreflex sensitivity
- Procedure: Glucose tolerance assessment
- Dietary Supplement: oral nutrition supplements
- Behavioral: Two day food records
- Behavioral: Food Frequency Questionnaire
- type
- PLACEBO_COMPARATOR
- label
- Healthy volunteers
- description
- Healthy men, age 18-50 years old
- interventionNames
- Procedure: Dexa scan
- Procedure: audiogram
- Procedure: measurement of heart rate variability and baroreflex sensitivity
- Procedure: Glucose tolerance assessment
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with disseminated testicular cancer undergoing first line cisplatin based chemotherapy (BEP or EP). * Age 18-50 years at start of treatment. * Signed informed consent. * Ability to comprehend Dutch (both reading and writing). * Complete remission after cisplatin based chemotherapy (BEP or EP) with or without adjunctive surgery and in active follow-up (only for crosssectional part of the study). Exclusion Criteria: * Mental disability * Patients with co-morbidities that affect gustatory or olfactory function, such as rhinosinusitis, liver or renal problems, hyperactivity or hypoactivity of the thyroid gland, diabetes, or neurologic disorders (only for crosssectional part of the study).
References
Publications (0)
Data not yet available